Redefining CAR-T Speed And Strength With DAR-T™: A Conversation With Nicholas Kirian

Autologous CAR-T manufacturing faces significant hurdles, including extended patient wait times, the risk of producing exhausted T-cell subsets, and high manufacturing costs. The DAR-T™ platform addresses these challenges by drastically shortening the manufacturing cycle from up to two weeks to just three days.

This super-short process not only cuts labor and material costs but also yields a final product enriched with younger, less-differentiated T-cells, specifically naïve and central memory subsets. This younger phenotype correlates with improved long-term outcomes and enhanced metabolic fitness in vivo. Furthermore, DAR-T cells demonstrate four times the potency and a stronger functional response against tumor targets compared to conventional cells. The platform is also underpinned by advanced digitalization, utilizing MES and LIMS systems to automate data capture and enable review by exception, accelerating product release to a targeted seven-day turnaround.

Discover how this integrated, high-velocity approach is redefining standards in cell therapy production.